Market
Synopsis:
The increase in the geriatric population is one of the significant
drivers of acute intermittent porphyria
market. According to reports, the aging population will almost double up by the
end of 2050. Market Research Future (MRFR) has revealed in its latest report that the global acute intermittent porphyria market share will thrive steadily at 4.50 %
during the forecast period 2022-2030.
The risk factors associated with acute
intermittent porphyria, which include liver cancer (hepatocellular carcinoma),
kidney failure, neurological disorders, psychiatric issues, gastrointestinal
problems, urinary tract issues, etc. will accelerate the market expansion. The
growth of the market is also attributable to the increasing prevalence of the metabolic disorders which is likely to
increase further during the assessment
period.
Other factors responsible for the market
proliferation include developments in the healthcare
sector, adoption of latest technologies for diagnosis, drug discoveries for
treatment, clinical trials by key
players, increased disposable income, population explosion, etc. However,
factors that will restrict the market growth across the assessment period
include the availability of expensive
treatment and poor reimbursement policies in the developing regions.
Market
Segmentation:
By diagnosis, the global acute intermittent
porphyria market has been segmented into
blood test, urine test, serum test, DNA test, and others.
By treatment, acute intermittent porphyria
market is segmented into
gonadotropin-releasing hormone analogues,
prophylactic hematin infusions, and others.
By end user, the global acute intermittent
porphyria market has been segmented into
hospitals & clinics, research centers, and others.
Regional
Analysis:
By region, the acute intermittent porphyria market
research
report has been segmented into North America & South
America, Europe, Asia Pacific, and, the Middle East & Africa. The North
America & South America region will generate maximum revenue from the
market during the projection period. The technological advancements integrated
into the treatment of acute intermittent porphyria is likely to accelerate
revenue creation over the review period. Other factors responsible for the
growth of the market include increasing patient with genetic metabolic
disorders, rising healthcare expenditure,
and increasing government support for
research & development. Furthermore, the concentration of key players in the region coupled with
increased research & development activities will encourage the market
growth and expansion.
Europe is the second largest market for
acute intermittent porphyria globally. The favorable factors supporting the
market expansion in the region are initiatives undertaken by the governments
and the availability of funds for research
& development activities. The presence of developed economies in the region is also likely to propel the market
growth.
Asia Pacific will exhibit the
steepest rise in growth of the market. The increasing geriatric population in
the region is one of the primary drivers of the market. Asian Development Bank
has estimated that by 2050, 15% of the total population of Malaysia will be
from over 65 years age group, and in China, the aging population will surpass
300 million. Furthermore, the booming healthcare sector, technological
developments, huge patient population,
high healthcare expenditure, etc. will
favor the market proliferation throughout the projection period.
The Middle East & Africa will exhibit
sluggish growth due to limited screening, ignorance of diseases, and poor access to treatment.
Competitive
Dashboard:
The key players profiled by MRFR in its
report include Dahaner (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Siemens AG (U.S.), Sysmex Corporation
(Japan), ARKRAY, Inc. (Japan), ACON Laboratories, Inc. (U.S.), and, F.
Hoffmann-La Roche Ltd (Switzerland) among others. The players strive to gain prominence in the market by devising and
employing strategies such as research & development, clinical trials,
acquisitions & mergers, innovative collaborations, agreements, etc.
Industry
Developments:
In January 2018, Alnylam Pharmaceuticals,
Inc., a biopharmaceutical company, has announced the expansion of Alnylam Act.
The program will include free third-party genetic testing and counseling for
Acute Hepatic Porphyrias (AHPs) which include four diseases- acute intermittent
porphyria, hereditary deficit of
delta-aminolevulinic acid dehydratase, hereditary coproporphyria, and, variegate porphyria.
About
Market Research Future:
At
Market Research Future (MRFR), we enable our customers to unravel the
complexity of various industries through our Cooked Research Report (CRR),
Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have
supreme objective to provide the optimum quality market research and
intelligence services to our clients.
Contact
us:
Market
Research Future (part of Wantstats Research and Media Private Limited),
99
Hudson Street, 5Th Floor,
New
York, New York 10013
United
States of America
+1 628
258 0071
Email:
sales@marketresearchfuture.com
Comments
Post a Comment